Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 603-622
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 73
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Gloria M. Gager, Dirk von Lewinski, Harald Sourij, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112169-112169
Open Access | Times Cited: 45
Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial
Hiroki Teragawa, Atsushi Tanaka, Kanae Takahashi, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Jennifer Matthews, Lakshini Y. Herat, Markus P. Schlaich, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14243-14243
Open Access | Times Cited: 10
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention
Tooba Laeeq, Maheen Ahmed, Hina Sattar, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1325-1325
Open Access | Times Cited: 3
Myocardial Infarction
Mukesh Nandave
(2024), pp. 249-318
Closed Access | Times Cited: 3
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy
Davide Viggiano, Rashmi Joshi, Gianmarco Borriello, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1241-1241
Open Access
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Reza Amani‐Beni, Bahar Darouei, Davood Shafie, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Zi‐Wei Yin, Huizhen Zheng, Zhihua Guo
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 16
Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
Lakshini Y. Herat, Jennifer R. Matthews, Wei E. Ong, et al.
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 12
Open Access | Times Cited: 15
Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats
Tingting Zhang, Xinyu Wang, Zhongli Wang, et al.
Pharmacology (2023) Vol. 108, Iss. 5, pp. 478-491
Open Access | Times Cited: 8
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2022) Vol. 130, Iss. S 01, pp. S80-S112
Open Access | Times Cited: 9
Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
Maura Brioschi, Yuri D’Alessandra, Massimo Mapelli, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1037-1037
Open Access | Times Cited: 4
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Michael Gotzmann, Pauline Henk, Ulrik Stervbo, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4458-4458
Open Access | Times Cited: 4
Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression
R Huttunen, A-M Haapanen-Saaristo, Anja Hjelt, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117453-117453
Open Access | Times Cited: 1
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
Sidar Çöpür, Abdullah Burak Yıldız, Adrian Covic, et al.
European Journal of Clinical Investigation (2023)
Open Access | Times Cited: 3
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice
Gianfranco Sinagra, Linda Pagura, Davide Stolfo, et al.
European Journal of Internal Medicine (2021) Vol. 90, pp. 10-15
Open Access | Times Cited: 7
Shen-Yuan-Dan Capsule Attenuates Verapamil-Induced Zebrafish Heart Failure and Exerts Antiapoptotic and Anti-Inflammatory Effects via Reactive Oxygen Species–Induced NF-κB Pathway
Xiang Li, Hongxu Liu, Yue Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 6
Cardiologia Teoria e Prática - Edição XIV
Guilherme Barroso Langoni de Freitas, Lara Sobreira Ferraz Egidio, João Augusto Camargo Moreira, et al.
(2024)
Open Access
Cardio-Renal Effects of SGLT2 Inhibitors in Diabetics and Non-Diabetics
Jennifer Matthews, Lakshini Y. Herat, Markus P. Schlaich, et al.
(2023)
Open Access | Times Cited: 1
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Medine Cumhur Cüre, Erkan Cüre
Current Pharmaceutical Design (2024) Vol. 30, Iss. 15, pp. 1149-1156
Closed Access
Page 1 - Next Page

Scroll to top